CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced the issuance of US patent 7,176,296 (the ‘296 patent) for oligonucleotide compounds having immunostimulatory activity. The claims of this patent, entitled “Modulation of Oligonucleotide CpG Mediated Immune Stimulation by Positional Modification of Oligonucleosides” cover compounds comprising a synthetic immunostimulatory motif and an immunomodulatory moiety. The claimed synthetic immunostimulatory motif may contain guanosine or a substituted guanosine, including 7-deazaguanosine or inosine. The claimed immunomodulatory moiety includes a variety of compositions, including a 3’-3’ linkage. The Company was previously granted similar claims in Europe (EU 1,278,761) and Australia (AU 2001257366).
